Pfizer Inc.’s “extraordinary cooperation” in disclosing and dealing with a subsidiary’s improper payments to foreign officials helped the company obtain a deferred prosecution agreement for violations of the U.S. Foreign Corrupt Practices Act.
On Aug. 7, Pfizer settled two parallel investigations by the U.S. Department of Justice and the Securities and Exchange Commission...
Welcome to Scrip
Create an account to read this article
Already a subscriber?